Elevance Health (ELV) Q1 2025: Carillon Services Grows 60%, Accelerating External Platform Leverage

April 22, 2025 | By EarningsIQ Research

Carillon, Elevance’s health services platform, posted over 60% growth in Q1, validating the company’s externalization strategy and diversified execution beyond core insurance. Margin discipline and targeted MA growth offset Medicaid headwinds, while digital and value-based care initiatives continue to drive enterprise integration. Guidance reiteration reflects management’s confidence in balancing elevated trend with operational rigor.

Summary

• Carillon Platform Expansion: Carillon’s 60% growth highlights the success of Elevance’s external services push.
• Margin Resilience Amid Medicaid Trend: Prudent expense management and targeted MA growth offset Medicaid cost pressures.
• Guidance Confidence Holds: Management reaffirms full-year outlook, citing operational discipline and diversified growth levers.

Performance Analysis

Elevance Health delivered a quarter marked by robust top-line growth and operational discipline, driven by premium yield, Medicare Advantage (MA) and ACA membership gains, and CarillonRx product revenue. Operating revenue grew over 15% year-over-year, reflecting both organic expansion and recent acquisitions, particularly in pharmacy and home health. The company’s health benefits segment remained the primary revenue driver, supported by higher premium yields and membership retention, while Carillon, the health services platform, contributed an outsized share of operating gain growth.

Cost trends in Medicaid remained elevated but manageable, with the consolidated benefit expense ratio rising 80 basis points year-over-year. However, this was partially offset by favorable Medicare Part D seasonality and disciplined operating expense control, which improved the adjusted operating expense ratio by 60 basis points. Carillon’s operating gain surged 34%, fueled by pharmacy volume and risk-based care performance. Operating cash flow was impacted by timing-related items but is expected to normalize, supporting unchanged guidance. Share repurchases continued opportunistically, reflecting confidence in the company’s valuation and capital flexibility.

• Carillon Services Outperformance: 60% growth in Carillon Services, with balanced internal and external momentum, positions Elevance as a platform operator, not just an insurer.
• Medicaid Trend Headwind Managed: Elevated Medicaid costs pressured benefit ratios, but rate alignment and operational efficiency mitigated impact.
• Prudent Membership Growth: MA and ACA membership increased, with retention and targeted growth sustaining margin and risk discipline.

Overall, Elevance’s performance underscores the benefits of a diversified, integrated model, with services, pharmacy, and risk-based care providing counterweights to legacy insurance cyclicality.

Executive Commentary

Strategic Positioning

1. Carillon: Services Platform as Growth Flywheel

Carillon, Elevance’s health services arm, is now a material growth engine, posting over 60% growth in Q1 and tracking to at least 50% for the year. Notably, growth is balanced between internal expansion (serving Elevance’s own plans) and external client wins, including Blues plans and other payers. CarillonRx, the pharmacy segment, is scaling through specialty pharmacy acquisitions (BioPlus, Kroger Specialty) and patient-centric migration, reinforcing Elevance’s ambition to become an integrated health services platform, not just a payer.

2. Value-Based and Digital Care Integration

Digital investments and value-based care models are being scaled across lines of business, with HealthOS now supporting 88,000 providers and 1,200 organizations. The expansion of value-based oncology to MA, elimination of prior auth for high-performing providers, and integration of home/community-based services (CareBridge) are all driving both quality and cost outcomes. These initiatives are central to Elevance’s “whole health” model, which targets both medical and pharmacy savings and improved member experience.

3. Risk and Margin Management in Government Programs

Medicaid and Medicare remain areas of disciplined execution, with ongoing rate alignment negotiations and a focus on stable, sustainable margins. Elevated Medicaid cost trend was anticipated and is being addressed through rate updates and product mix management. In Medicare Advantage, growth is targeted, with strong retention and a disciplined approach to benefit design and risk adjustment (including V28 model adaptation and Part D IRA changes). Management is prioritizing long-term sustainability over volume at risk of margin dilution.

4. Commercial Momentum and Employer Engagement

Commercial lines are benefiting from integrated offerings, with patient advocacy, behavioral health, and specialty care bundled to appeal to employers seeking holistic solutions. Early signals from the 2026 selling season are positive, and ACA expansion into three new states is designed to build lifetime value by coordinating ACA and Medicaid coverage, despite near-term effectuation rate softness.

Key Considerations

Elevance’s Q1 results reflect a strategic pivot toward platform-based, diversified healthcare delivery, with services, digital, and value-based models increasingly central. The company is actively managing risk and margin headwinds in government programs while leveraging Carillon’s external traction and pharmacy scale.

Key Considerations:

• Carillon Externalization: External payer adoption of Carillon services validates the platform thesis and opens new revenue streams beyond core insurance.
• Medicaid Rate Alignment: Ongoing state negotiations are crucial for restoring Medicaid margin, with July rate updates covering one-third of membership as a key watchpoint.
• Part D and V28 Risk Model Adaptation: Early adaptation to regulatory changes in Medicare drug and risk adjustment models is supporting stable MA margins, but continued vigilance is required.
• Digital and Home-Based Care Integration: HealthOS and CareBridge scale-up are differentiators in provider engagement and cost containment.
• Capital Flexibility: Debt-to-capital at 41% and continued share repurchases provide optionality for further strategic investment and buybacks.

Risks

Elevated Medicaid cost trend and dependence on timely state rate updates present ongoing margin risk, particularly if acuity outpaces reimbursement. Regulatory uncertainty in Medicare (V28, IRA, risk adjustment) could pressure future bids and margins. Commercial ACA effectuation softness and macro-driven utilization spikes (e.g., flu, respiratory) remain variables to monitor, though management has embedded prudent assumptions into guidance. Execution risk in scaling Carillon and integrating recent acquisitions also warrants attention.

Forward Outlook

For Q2 2025, Elevance guided to:

• Continued elevated benefit expense ratios, with cost trends in Medicaid and Medicare managed within expectations.
• Stable operating expense ratios, reflecting ongoing discipline and integration of recent acquisitions.

For full-year 2025, management reiterated guidance:

• Adjusted diluted EPS of $34.15 to $34.85, with more than 60% of earnings expected in the first half.

Management highlighted several factors that will shape the year:

• Medicaid rate alignment and July renewals as key margin inflection points.
• Carillon external growth and pharmacy integration as drivers of diversified earnings.

Takeaways

Elevance’s strategic evolution toward an integrated, platform-based model is gaining traction, with Carillon’s externalization and pharmacy scale delivering both growth and risk diversification. Margin pressures in government programs are being actively managed, but remain a watchpoint as rate cycles and regulatory changes play out.

• Platform Leverage: Carillon’s 60% growth and external payer wins signal a credible shift from pure-play insurance to health services platform, with implications for long-term multiple expansion.
• Margin Management: Disciplined MA and Medicaid execution, coupled with digital and value-based care integration, are helping offset trend headwinds and stabilize earnings.
• Future Watch: Medicaid rate cycles, Carillon’s continued external traction, and regulatory adaptation in Medicare will be key drivers of valuation and narrative in the coming quarters.

Conclusion

Elevance Health’s Q1 2025 results validate its pivot toward a diversified, platform-driven healthcare model, with Carillon’s external momentum and disciplined government program management offsetting cyclical trend headwinds. Continued execution on digital, value-based, and home-based care integration is key to sustaining growth and margin resilience through 2025 and beyond.

Industry Read-Through

Elevance’s results highlight a broader industry shift toward platform and services externalization, with payers leveraging digital, pharmacy, and home-based care to diversify revenue and mitigate insurance cyclicality. Carillon’s external growth, especially with Blues plans, signals that health services arms can compete for share across the payer landscape. The company’s experience managing Medicaid and Medicare trend and regulatory adaptation offers a read-through for peers facing similar headwinds, underscoring the importance of operational discipline, rate negotiation, and integrated care delivery in sustaining earnings power. Investors should monitor the pace of services externalization and the impact of regulatory cycles on risk-bearing businesses across managed care.

ELV Healthcare Managed care Health services Platform Medicaid Pharmacy Value-based care